Sigma receptor ligand, (+)-pentazocine, suppresses inflammatory responses of retinal microglia

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 6, 2014, Pages 3375-3384

  Zhao, Jing ^a   Ha, Yonju ^a   Liou, Gregory I ^a   Gonsalvez, Graydon B ^a   Smith, Sylvia B ^a   Bollinger, Kathryn E ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Microglia; Neuron glia interactions; Optic nerve; Sigma receptor

Indexed keywords

INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PENTAZOCINE; PENTAZOCINE ANTAGONIST; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DENSITOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE MICROSCOPY; MICROGLIA; MTT ASSAY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RETINITIS; WESTERN BLOTTING;

MICROGLIA; NEURON-GLIA INTERACTIONS; OPTIC NERVE; SIGMA RECEPTOR;

ANIMALS; BLOTTING, WESTERN; CELL COUNT; CELL SURVIVAL; CYTOKINES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MICROGLIA; MITOGEN-ACTIVATED PROTEIN KINASES; OPTIC NERVE; PENTAZOCINE; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, SIGMA; RETINAL GANGLION CELLS; RETINITIS;

EID: 84901916541     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-12823     Document Type: Article

References (46)

1. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 1996;19:312-318.
2. Streit WJ, Mrak RE, Griffin WS. Microglia and neuroinflammation: a pathological perspective. J Neuroinflammation. 2004;1:14.
3. Bhat NR, Zhang P, Lee JC, Hogan EL. Extracellular signal-regulated kinase and p38 subgroups of mitogen-activated protein kinases regulate inducible nitric oxide synthase and tumor necrosis factor-alpha gene expression in endotoxin-stimulated primary glial cultures. J Neurosci. 1998;18:1633-1641.
4. Waetzig V, Czeloth K, Hidding U, et al. c-Jun N-terminal kinases (JNKs) mediate pro-inflammatory actions of microglia. Glia. 2005;50:235-246.
5. Zhang P, Hogan EL, Bhat NR. Activation of JNK/SAPK in primary glial cultures: II, differential activation of kinase isoforms corresponds to their differential expression. Neurochem Res. 1998;23:219-225.
6. Langmann T. Microglia activation in retinal degeneration. J Leukoc Biol. 2007;81:1345-1351.
7. Zeng HY, Zhu XA, Zhang C, et al. Identification of sequential events and factors associated with microglial activation, migration, and cytotoxicity in retinal degeneration in rd mice. Invest Ophthalmol Vis Sci. 2005;46:2992-2999.
8. Gebicke-Haerter PJ. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech. 2001;54:47-58.
9. Hellewell SC, Morganti-Kossmann MC. Guilty molecules, guilty minds: the conflicting roles of the innate immune response to traumatic brain injury. Mediators Inflamm. 2012;2012: 356494.
10. Perry VH, Nicoll JA, Holmes C. Microglia in neurodegenerative disease. Nat Rev Neurol. 2010;6:193-201.
11. Liou GI. Diabetic retinopathy: role of inflammation and potential therapies for anti-inflammation. World J Diabetes. 2010;1:12-18.
12. Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Curr Opin Pharmacol. 2013; 13:23-31.
13. Buschini E, Piras A, Nuzzi R, Vercelli A. Age related macular degeneration and drusen: neuroinflammation in the retina. Prog Neurobiol. 2011;95:14-25.
14. Roh MZY, Murakami Y, Thanos A, et al. Etanercept, a widely used inhibitor of tumor necrosis factor-α(TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One. 2012;7:e40065.
15. Cukras CA, Petrou P, Chew EY, Meyerle CB, Wong WT. Oral minocycline for the treatment of diabetic macular edema (DME): results of a phase I/II clinical study. Invest Ophthalmol Vis Sci. 2012;53:3865-3874.
16. Hayashi TST. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell. 2007;131:596-610.
17. Ha YSA, Tawfik A, Williams C, et al. Late-onset inner retinal dysfunction in mice lacking sigma receptor 1 (σR1). Invest Ophthalmol Vis Sci. 2011;52:7749-7760.
18. Ola MSMP, El-Sherbeny A, Roon P, et al. Expression pattern of sigma receptor 1 mRNA and protein in mammalian retina. Brain Res Mol Brain Res. 2001;95:86-95.
19. Hayashi TST. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr Neuropharmacol. 2005;3: 267-280.
20. Nishimura TIT, Iyo M, Hashimoto K. Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways. PLoS One. 2008;3:e2558.
21. Takebayashi MHT, Su TP. A perspective on the new mechanism of antidepressants: neuritogenesis through sigma-1 receptors. Pharmacopsychiatry. 2004;37(suppl 3):S208-S213.
22. Mueller BH II, Park Y, Daudt DR III, et al. Sigma-1 receptor stimulation attenuates calcium influx through activated L-type voltage gated calcium channels in purified retinal ganglion cells. Exp Eye Res. 2013;107:21-31.
23. Tchedre KT, Huang RQ, Dibas A, et al. Sigma-1 receptor regulation of voltage-gated calcium channels involves a direct interaction. Invest Ophthalmol Vis Sci. 2008;49:4993-5002.
24. Hall AAHY, Ajmo CT Jr, Cuevas J, Pennypacker KR. Sigma receptors suppress multiple aspects of microglial activation. Glia. 2009;57:744-754.
25. Mancuso ROS, Rando A, Casas C, Osta R, Navarro X. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9:814-826.
26. Allahtavakoli MJB. Sigma-1 receptor ligand PRE-084 reduced infarct volume, neurological deficits, pro-inflammatory cytokines and enhanced anti-inflammatory cytokines after embolic stroke in rats. Brain Res Bull. 2011;85:219-224.
27. Smith SBDJ, Dun Y, Mysona B, Roon P, Martin PM, Ganapathy V. In vivo protection against retinal neurodegeneration by sigma receptor 1 ligand (+)-pentazocine. Invest Ophthalmol Vis Sci. 2008;49:4154-4161.
28. Ruscher KIA, Valind K, Rowshan Ravan A, Kuric E, Wieloch T. Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke. PLoS One. 2012;7:e45118.
29. Tuerxun TNT, Adachi N, Kumamaru E, Kitazawa H, Kudo M, Kunugi H. SA4503, a sigma-1 receptor agonist, prevents cultured cortical neurons from oxidative stress-induced cell death via suppression of MAPK pathway activation and glutamate receptor expression. Neurosci Lett. 2010;469:303-308.
30. Ola MS, Moore P, Maddox D, et al. Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res. 2002;107:97-107.
31. El-Remessy ABTY, Zhu G, Matragoon S, et al. Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation. Mol Vis. 2008;14:2190-2203.
32. Dun YTM, Prasad P, Ganapathy V, Smith SB. Prevention of excitotoxicity in primary retinal ganglion cells by (+)-pentazocine, a sigma receptor-1 specific ligand. Invest Ophthalmol Vis Sci. 2007;48:4785-4794.
33. Martin PMOM, Agarwal N, Ganapathy V, Smith SB. The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res. 2004;123:66-75.
34. DeCoster MA, Klette KL, Knight ES, Tortella FC. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res. 1995;671:45-53.
35. Lysko PG, Gagnon RC, Yue TL, Gu JL, Feuerstein G. Neuroprotective effects of SKF 10,047 in cultured rat cerebellar neurons and in gerbil global brain ischemia. Stroke. 1992;23:414-419.
36. Moriyama NTM, Miyano K, Miyoshi M, Watanabe T. ANP inhibits LPS-induced stimulation of rat microglial cells by suppressing NF-kappaB and AP-1 activations. Biochem Biophys Res Commun. 2006;350:322-328.
37. Nakamura YSQ, Kataoka K. Lipopolysaccharide-induced microglial activation in culture: temporal profiles of morphological change and release of cytokines and nitric oxide. Neurosci Res. 1999;35:95-100.
38. Matsumoto RR, Bowen WD, Tom MA, et al. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol. 1995; 280:301-310.
39. Bourrié BBE, De Nys N, Esclangon M, et al. SSR125329A, a high affinity sigma receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol. 2002;456:123-131.
40. Casellas PGS, Bourrie B, Ferrini JB, Jbilo O, Vidal H. SR31747A: a peripheral sigma ligand with potent antitumor activities. Anticancer Drugs. 2004;15:113-118.
41. Langa FCX, Tovar V, Lavado A, et al. Generation and phenotypic analysis of sigma receptor type I (sigma 1) knockout mice. Eur J Neurosci. 2003;18:2188-2196.
42. Mavlyutov TANR, Guo LW. Accelerated retinal ganglion cell death in mice deficient in the Sigma-1 receptor. Mol Vis. 2011; 17:1034-1043.
43. Ibrahim ASE-SM, Peña A Jr, Liou GI. Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Mol Vis. 2010;16:2033-2042.
44. Nakajima K, Tohyama Y, Kohsaka S, Kurihara T. Protein kinase C alpha requirement in the activation of p38 mitogen-activated protein kinase, which is linked to the induction of tumor necrosis factor alpha in lipopolysaccharide-stimulated microglia. Neurochem Int. 2004;44:205-214.
45. Moriguchi S, Yamamoto Y, Ikuno T, Fukunaga K. Sigma-1 receptor stimulation by dehydroepiandrosterone ameliorates cognitive impairment through activation of CaM kinase II, protein kinase C and extracellular signal-regulated kinase in olfactory bulbectomized mice. J Neurochem. 2011;117:879-891.
46. Tan FG-AP, Downes C, Zhang M, O'Donovan L, Callaway JK, Crack PJ. The σ1 receptor agonist 4-PPBP elicits ERK1/2 phosphorylation in primary neurons: a possible mechanism of neuroprotective action. Neuropharmacology. 2010;59:416-424.